Background: Previous studies have shown that the arterial wall is a potential source of inflammatory markers in COPD. Here, we sought to compare the expression of acute phase reactants (APRs) in COPD patients and controls both at the local (pulmonary arteries and lung parenchyma) and systemic (peripheral blood leukocytes and plasma) compartments. Methods: Consecutive patients undergoing elective surgery for suspected primary lung cancer were eligible for the study. Patients were categorized either as COPD or control group based on the spirometry results. Pulmonary arteries and lung parenchyma sections, peripheral blood leukocytes, and plasma samples were obtained from all participants. Gene expression levels of C-reactive protein (CRP) and serum amyloid A (SAA1, SAA2, and SAA4) were evaluated in tissue samples and peripheral blood leukocytes by reverse transciption-PCR. Plasma CRP and SAA protein levels were measured by enzyme-linked immunosorbent assays. Proteins were evaluated in paraffin-embedded lung tissues by immunohistochemistry. Results: A total of 40 patients with COPD and 62 controls were enrolled. We did not find significant differences in the gene expression between COPD and control group. Both CRP and SAA were overexpressed in the lung parenchyma compared with pulmonary arteries and peripheral blood leukocytes. The expression of SAA was significantly higher in the lung parenchyma than in the pulmonary artery (2-fold higher for SAA1 and SAA4, P=0.015 and P<0.001, respectively; 8-fold higher for SAA2, P<0.001) and peripheral blood leukocytes (16-fold higher for SAA1, 439-fold higher for SAA2, and 5-fold higher for SAA4; P<0.001).
Introduction
Although the presence of systemic inflammation has been extensively documented in patients with COPD, its exact sources are still unclear. 1 Moreover, the question as to whether the systemic inflammatory response may influence the clinical manifestations and the expression of different COPD phenotypes remains open.
C-reactive protein (CRP) and serum amyloid A (SAA) are among the most common acute phase reactants (APRs) found to be increased in COPD, 3, 4 even though their biological sources have not been yet identified. 5 It has been hypothesized that the excess production of local inflammatory mediators in the pulmonary compartment may spill over into the systemic circulation. 6 However, this possibility is contradicted by the lack of correlation between local and systemic expression of inflammatory biomarkers in COPD. 7 Moreover, markers of inflammation in the induced sputum did not show a significant association with their plasma levels. 6 Previous investigations conducted in normal tissues as well as animal and in vitro studies demonstrated that lung tissues are able to synthesize and secrete APRs. 3, 8, 9 We have previously shown that bronchi and the lung parenchyma are able to synthesize CRP and SAA in COPD as compared with smokers who did not develop the disease (control group), 10 with potential distinct roles for fibroblasts, epithelial cells, and macrophages. 11 Notably, our immunohistochemical observations revealed an increased expression of APRs in the arterial wall of pulmonary vessels. Therefore, it is possible that blood vessels or cells may be responsible for these observations. The role of pulmonary arteries and peripheral blood leukocytes as a potential source of systemic inflammatory markers in COPD has not yet been evaluated. The potential involvement of the arterial wall and/or peripheral blood leukocytes in COPD inflammation would also explain the well-known association of this condition with adverse cardiovascular events. 12 We therefore designed the current case-control study to compare the expression of APRs in COPD patients and controls both at the local (pulmonary arteries and lung parenchyma) and systemic (peripheral blood leukocytes and plasma) compartments.
Methods

Study participants
Consecutive patients with suspected primary lung cancer who were scheduled for elective pneumectomy or lobectomy were eligible. Patients were approached for the study the day before scheduled surgery. Exclusion criteria were as follows: 1) age <40 years, 2) a history of acute respiratory infections in the previous 2months, 3) a previously diagnosed neoplasm, 4) treatment with radiotherapy and/or chemotherapy, 5) presence of chronic inflammatory diseases, and 6) autoimmune diseases. The amount of time spent between the opening of the cutaneous layer and the extraction of the anatomical sample was measured in all participants. Cases with an elapsed time >3 hrs were excluded because of the potential surgery-related increase in inflammatory markers. Patients had their medical records checked to ensure that they recently underwent a lung function test. Participants with a /FVC ratio <0.7 post-bronchodilator were considered as having COPD. The patients were classified according to the stage of the disease following the instructions of the GOLD. All of the remaining was considered controls. The study participants completed a standardized questionnaire focusing on their medical history, tobacco smoking habits, and current use of drugs. The Charlsonage comorbidity index is a measure of comorbidity that was developed as a prospectively applicable method for classifying comorbid conditions which might alter the risk of morality for use in longitudinal studies. 13 The TNM staging of the primary lesion 14 and the surgical approach were also recorded. A lung specimen was submitted for microbiological examination before surgical resection to evaluate microbial colonization. Microbiological samples obtained with bronchoscopy were also examined. After surgery, a section of the lung parenchyma and the largest available section of the resected pulmonary artery were collected for further study. Samples that were most distally located from the primary lesion were identified and immediately processed. The remaining anatomical sample was submitted for pathological diagnosis of the primary lesion. Peripheral venous blood samples were collected before surgery in all participants. This study was conducted in accordance with the Declaration of Helsinki.
Gene expression levels in tissues and blood
Expression of inflammatory markers in tissues and peripheral blood leukocytes was analyzed using reverse transcription quantitative PCR(RT-qPCR), a method consisting of three steps (RNA extraction, reverse transcription to cDNA, and gene amplification). RNA was isolated from fresh tissues with a TriSure kit (Bioline, London, UK). Samples subsequently underwent DNase treatment using RNase-free DNase (QIAGEN GmbH, Hilden, Germany) and cDNA was synthesized using an iScript™ cDNA synthesis kit (Bio-Rad, Hercules, CA, USA 
Immunohistochemistry
Tissue blocks from the subpleural parenchyma (paying attention to avoid areas involved by the tumor) were fixed in 10% formalin and embedded in paraffin. Five-μm-thick sections were prepared for immunohistochemical analysis. Mouse monoclonal antibodies against SAA1 (Novus Biologicals, Cambridge, UK) and CRP (Abcam, Cambridge UK) were used. Antigen retrieval was achieved by microwave heat treatment in citrate buffer (Dako, Glostrup, Denmark) at 98°C for 15 mins. The bound antibody was developed with diaminobenzidine using a Dako Envision staining kit (K4065) according to manufacturer's recommendations. Stained sections were observed under light microscope by two independent observers. All immunohistochemical studies included appropriate standard quality controls. As a negative control, immunohistochemistry was performed using secondary antibodies without the primary antibody.
Statistical analysis
Means and SDs for continuous variables and frequencies and percentages for categorical variables were estimated. Relative gene expression values were evaluated with the 2 −ΔΔCt method 16 to compare COPD and control group, and according to the anatomical location. The Student's t-test was used to test for differences in continuous variables between COPD patients and controls. Categorical data were compared with the χ 2 test. The associations between tissue gene expression and plasma levels of inflammatory biomarkers were analyzed with the Spearman's rank correlation coefficient. Analyses were adjusted for gender and pack-years smoked. All testing hypotheses were performed at a 5% level of significance (two-tailed), using the statistical software IBM SPSS Statistics version 20.0 (IBM Corporation, Somers, NY, USA).
Results
Patients and procedures
Forty patients with COPD were included in the study. The main characteristics of the study participants are summarized in Expression of acute phase reactants in the lung parenchyma CRP and SAA gene expression in the lung parenchyma was higher in COPD patients than in controls ( Figure 1A) ; Table 1 Primers used for reverse transcription quantitative PCR
Gene
Forward primer Reverse primer
however, the expression did not differ significantly between the two groups (P>0.05). In the lung parenchyma, we found significant positive correlations between the expression of CRP with SAA1 and SAA4; SAA1 with SAA2 and SAA4; and SAA2 with SAA4 (Table 3 ). Significant differences in terms of SAA4 expression were observed between controls and GOLD III COPD (P=0.034), as well as between GOLD II and GOLD III COPD (P=0.044). SAA4 expression in the lung parenchyma increased in parallel with the severity of the disease ( Figure 1B ).
Expression of acute phase reactants in the pulmonary artery CRP expression in the pulmonary artery was higher in COPD patients than in controls ( Figure 2A ). Moreover, SAA2 expression was 100% higher in COPD patients than in controls (P=0.028; Figure 2A ). In the pulmonary artery, we found significant positive correlations between the expression of CRP and SAA1, 2 and 4, as well as between SAA1 and SAA2 (Table 3 ). Significant differences in terms of SAA2 expression were observed between resistant smokers and GOLD I COPD patients (P=0.010), as well as between GOLD I and GOLD II COPD (P=0.012; Figure 2B ).
Expression of acute phase reactants in peripheral blood leukocytes
Expression of CRP, SAA1, and SAA4 in peripheral blood leukocytes was found to differ significantly between COPD patients and controls. In line with the results obtained in the pulmonary artery, SAA2 expression was twofold higher in COPD patients than in controls ( Figure 3A ). There was a significant positive correlation between the expression of CRP and SAA1 and SAA4; and SAA1 and SAA4 (Table 3) . We found significant differences between GOLD I COPD and controls in terms of SAA1 (P=0.037) and SAA4 (P=0.018) expression ( Figure 3B and C). In addition, significant differences in terms of SAA4 expression were observed between GOLD I and GOLD II COPD (P=0.030).
Comparison of acute phase reactants expression in different tissues
We then performed a comparison of APRs expression in the lung parenchyma, pulmonary artery, and peripheral blood leukocytes (Figure 4 ). The expression of SAA was significantly higher in the lung parenchyma than in the pulmonary artery (2-fold higher for SAA1 and SAA4, P=0.015 and P<0.001, respectively; eightfold higher for SAA2, P<0.001) and peripheral blood leukocytes (16-fold higher for SAA1, 439-fold higher for SAA2, and fivefold higher for SAA4; P<0.001). Compared with peripheral blood leukocytes, the expression of SAA was significantly higher in the pulmonary artery (eightfold higher for SAA1, P<0.001; 50-fold higher for SAA2, P<0.001; and 2.3-fold higher for SAA4, P=0.019). However, no differences in CRP expression were observed in the lung parenchyma, pulmonary artery, and peripheral blood leukocytes. All findings were maintained after adjusting for gender and pack-years smoked. We failed to identify significant differences in the APRs expression according to the use of treatment.
Correlations between acute phase reactants expression in different tissues
Significant positive correlations were identified in the different tissues (Table 4 ). These findings were maintained after adjusting for gender and pack-years smoked. We failed to identify significant differences in the APRs expression according to the use of treatment.
Associations between acute phase reactants gene expression and their plasma concentrations
Plasma CRP showed a trend toward higher levels in COPD patients (4.4±1.73 mg/mL) than in control group (3.8±2.04 mg/mL, P>0.05). SAA concentrations in plasma were significantly higher in COPD patients (5.6±1.3 mg/ mL) than in controls (4.6±21 mg/mL, P=0.031). A significant positive association between plasma CRP and SAA levels was evident (P=0.617, P<0.001).
However, there was no significant correlation between plasma levels of APRs and their gene expression in the lung parenchyma, pulmonary artery, and peripheral blood leukocytes. SAA levels increased in parallel with the severity of COPD ( Figure 5A ) and CRP levels increased with the stage of the disease however these differences were not significant ( Figure 5B ).
Immunohistochemistry
Immunohistochemistry revealed an increased expression of both CRP and SAA in the lung tissue of COPD patients as compared to controls. As shown in Figure 6 , staining was chiefly captured by the small vessel wall, most markedly for SAA.
Discussion
In the current study, we performed a comparison of APRs expression in the lung parenchyma, pulmonary artery, and peripheral blood leukocytes of COPD patients. We also measured plasma CRP and SAA concentrations with the goal of establishing whether significant associations exist with their tissue gene expression. Our results indicate that the expression of ARPs is higher in the lung compared than in peripheral blood. Notably, we also observed that both SAA and CRP expression is more pronounced in the lung parenchyma than in the pulmonary artery. However, no association was found between the expression of inflammatory molecules in the lung and their circulating plasma levels.
Previous studies have consistently shown that COPD inflammation is not limited to the airways and lung, 17 but it can also be found at the systemic level. 18 Although increased circulating levels of CRP, IL-6, IL-8, and tumor necrosis factor-α have been reported in COPD patients, 19, 20 the exact sources of proinflammatory molecules in this clinical entity remain unclear. The most widely accepted model explaining systemic inflammation in COPD postulates that the excess production of local inflammatory mediators in the pulmonary compartment may spill over into the systemic circulation. 6 CRP is a well-known biomarker of both airflow obstruction 21 and systemic inflammation, 22 but less data are available on SAA as an inflammatory biomarker in COPD. Although our current findings generally indicate a more marked inflammatory reaction at the local rather than the systemic level, it seems that the lack of correlation with serum levels do not support the spillover hypothesis. The compartmentalization of CRP and SAA gene expression is a key factor that needs to be considered when analyzing inflammatory biomarkers in COPD. Although the disease is characterized by marked inflammation of the airways, lung parenchyma, and pulmonary vasculature, 23 the anatomical involvement may show a significant interindividual variability that ultimately results in different disease phenotypes. 24, 25 Aortic endothelial cells may secrete CRP 26 and SAA has been shown to be expressed in the endothelium. 27 However, no studies to date have focused on the potential role of the pulmonary vascular bed as a source of systemic inflammation in COPD. Our results indicate that SAA expression in COPD patients is higher in the lung parenchyma than in the pulmonary artery. In a previous immunohistochemical investigation, we have shown that SAA and CRP in COPD are both expressed in the pulmonary vessel wall. 10 Here, we expanded our previous observations by assessing their gene expression levels both in the lung and blood compartments. The higher expression levels of SAA in the lung parenchyma could be ascribed to small vessels (capillaries), which showed the most marked staining on immunohistochemistry. Interestingly, APRs were under-expressed in PBL from COPD as compared to controls. Although the differences are not significant, our interpretation is that probably the blood is a bad candidate as a potential contributor of systemic inflammation in COPD.
Some caveats of the current study merit comment. First, although the number of patients may be a limitation, the groups were balanced in the number of patients to make groups comparable in sample size. Second, quantification of mRNA does not provide Stage of the disease adjusted for gender and pack-years smoked because had significant differences in both groups, these not occur for BMI or age. The paper of BMI is especially relevant, since previous reports have informed about this potential association in different clinical conditions. 29 In our cohort, however, we were not able to show this relationship. The authors identified several associations between different inflammatory markers both at the local and systemic level. Further studies of the inflammatory responses in various compartments (eg, liver, sputum, or saliva) will be necessary to identify other potential sources of systemic inflammation in COPD. COPD is a heterogeneous disorder defined by the pulmonary function test. The pathogenesis would be different between subgroups such as the chronic bronchitis and pulmonary emphysema. Nevertheless, we had not differenced by phenotypes, specifically, we had not determinate the grade of emphysema, but all patients had centrilobular emphysema. Other limitation of our study is that the enrolled patients were all under surgery for suspected primary lung cancer and the number of patients in all groups is different, being the number of COPD patients in stage 3 small.
Conclusions
The inflammatory burden of COPD seems to be higher in the lung parenchyma than pulmonary arteries and peripheral blood leukocytes. Notably, no associations were noted between lung expression of APRs and their circulating plasma levels, making the leakage of inflammatory proteins from the lung to the bloodstream unlikely. Based on these results, other potential sources of systemic inflammation in COPD (eg, the liver) need further scrutiny.
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